trial

Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia

NCTId NCT02049021
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 20 (estimated)
Sponsored by University of Sao Paulo
Primary completion 2014-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
20 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2010-02
Primary completion
2014-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
MECTA SPECTRUM 5000Q ECT

Sponsors

University of Sao PauloLead Sponsor

Investigators

1
Hélio Elkis, MD PhDPrincipal Investigator

Sites

1 total
São Paulo, Brazil

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE4
Primary Completion Date
2014-01
Status
UNKNOWN
relationships
The graph out of here
drug
MECTA SPECTRUM 5000Q ECT
drug
lead_sponsor
University of Sao Paulo
company
indication
Refractory Schizophrenia
indication
Schizophrenia, Treatment-Resistant
indication
Schizophrenia
indication
investigator
Hélio Elkis, MD PhD
person